| http://www.w3.org/ns/prov#value | - roved by the U.S. Food and Drug Administration for the single-agent treatment of metastatic renal cell cancer, can also cause symptoms such as fatigue, nausea, vomiting, and diarrhea.[18,19] Response to interleukin-2 treatment varies; some patients gain weight, and some require nutritional support.[19] However, most patients taking interleukin gain weight.
|
